Researchers and opinion leaders have considered a number of potential solutions to the so-called antibody-related reproducibility crisis. One is to transition from traditional monoclonal antibodies to recombinant ones.*
So, what makes recombinant antibodies better and more effective than conventional hybridoma-derived ones? We asked six experts from the flow cytometry and antibody community to share their opinion and experience with recombinant antibodies.